Fig. 2.

Imaging protocols: FDG PET was performed at baseline (PET_baseline), within 2 weeks of the first pre-treatment. It was repeated for response evaluation at 3 months and at 6 months. Baseline ceCT was performed within 2 weeks of the start of pre-treatment and repeated at 3, 6, 9, and 12 months, 2–3 times after 1–2 years and once 2–5 years after ¹⁷⁷Lu lilotomab satetraxetan treatment. SPECT/CT imaging was performed at days 1, 4, and 7 (expect for in arm 1, where only day 4 and 7 SPECT/CT was performed) and used for dosimetry calculations. The 0-h time point indicates administration of ¹⁷⁷Lu-lilotomab satetraxetan